The progress made in determining the Mycobacterium tuberculosis structural proteome

Proteomics

Volumn 11, Issue 15, 2011, Pages 3128-3133

  Ehebauer, Matthias T ^a   Wilmanns, Matthias ^a  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

Microbiology; Mycobacterium tuberculosis; Protein structure; Structural proteomics

Indexed keywords

ALUVIRAN; AMINOOXAZOLE DERIVATIVE; AMPRENAVIR; BACTERIAL PROTEIN; ISONIAZID; NELFINAVIR; PROTEINASE INHIBITOR; PYRIDOPYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL GENOME; DRUG DESIGN; DRUG SYNTHESIS; DRUG TARGETING; GENE SEQUENCE; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STRUCTURAL PROTEOMICS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG DESIGN; MYCOBACTERIUM TUBERCULOSIS; PROTEIN CONFORMATION; PROTEOME; PROTEOMICS;

BACILLI (CLASS); MYCOBACTERIUM TUBERCULOSIS;

EID: 79960430601     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000787     Document Type: Review

References (35)

1. Hershkovitz, I., Donoghue, H. D., Minnikin, D. E., Besra, G. S. et al., Detection and molecular characterization of 9000-year- old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. PLoS One 2008, 3, e3426.
2. Zink, A. R., Sola, C., Reischl, U., Grabner, W. et al., Characterization of Mycobacterium tuberculosis complex DNAs from Egyptian mummies by spoligotyping. J. Clin. Micorbiol. 2003, 41, 359-367.
3. Kaufmann, S. H. E., in: Kaufmann, S. H. E., Rubin, E., (Eds.), Handbook of Tuberculosis: Clinics, Diagnostics, Therapy and Epidemiology, Wiley-VCH, Weinheim 2008, pp. XXIII-XXVII.
4. World Health Organization. Tuberculosis on the increase. World Health Forum 1993, 14, 1-94.
5. Barry, C. E., 3rd, Blanchard, J. S., The chemical biology of new drugs in the development for tuberculosis. Curr. Opin. Chem. Biol. 2010, 14, 456-466.
6. Chim, N., McMath, L. M., Beeby, M., Goulding, C. W., Advances in Mycobacterium tuberculosis structural genomics: investigating potential chinks in the armor of a deadly pathogen. Infect. Disord. Drug Targets 2009, 9, 475-492.
7. Arcus, V. L., Lott, J. S., Johnston, J. M., Baker, E. N., The potential impact of structural genomics on tuberculosis drug discovery. Drug Discov. Today 2006, 11, 28-34.
8. Holton, S., Weiss, M. S., Tucker, P. A., Wilmanns, M., Structure-based approaches to drug discovery against tuberculosis. Curr. Protein Pept. Sci. 2007, 8, 365-375.
9. Baker, E. N., Structural genomics as an approach towards understanding the biology of tuberculosis. J. Struct. Funct. Genomics 2007, 8, 57-65.
10. Wilmanns, M., Kaufmann, S. H. E., in: Kaufmann, S. H. E., Rubin, E. (Eds.), Handbook of Tuberculosis: Molecular Biology and Biochemistry, Wiley-VCH, Weinheim 2008, pp. 261-285.
11. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T. et al., Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence [Erratum in Nature 1998, 396, 190]. Nature 1998, 393, 537-544.
12. Camus, J., Pryor, M. J., Medigue, C., Cole, S. T., Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002, 148, 2967-2973.
13. Cooper, J. B., McIntyre, K., Badasso, M. O., Wood, S. P. et al., X-ray structure analysis of the iron-dependent superoxide dismutase from Mycobacterium tuberculosis at 2.0 Angstroms resolution reveals novel dimer-dimer interactions. J. Mol. Biol. 1995, 246, 531-544.
14. Goulding, C. W., Perry, L. J., Protein production in Escherichia coli for structural studies by X-ray crystallography. J. Struct. Biol. 2003, 142, 133-143.
15. Goulding, C. W., Perry, L. J., Anderson, D., Sawaya, M. R. et al., Structural genomics of Mycobacterium tuberculosis: a preliminary report of progress at UCLA. Biophys. Chem. 2003, 105, 361-370.
16. Poulsen, C., Holton, S., Geerlof, A., Wilmanns, M., Song, Y. H., Stoichiometric protein complex formation and over-expression using the prokaryotic native operon structure. FEBS Lett. 2010, 584, 669-674.
17. Gong, S., Worth, C. L., Bickerton, G. R., Lee, S. et al., Structural and functional restraints in the evolution of protein families and superfamilies. Biochem. Soc. Trans. 2009, 37, 727-733.
18. Manjunatha, U. H., Boshoff, H., Dowd, C. S., Zhang, L. et al., Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 2006, 103, 431-436.
19. Singh, R., Manjunatha, U., Boshoff, H. I. M., Ha, Y.-H. et al., PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008, 322, 1392-1395.
20. Cohen-Gonsaud, M., Barthe, P., Canova, M. J., Stagier-Simon, C. et al., The Mycobacterium tuberculosis Ser/Thr kinase substrate Rv2175c is a DNA-binding protein regulated by phosphorylation. J. Biol. Chem. 2009, 284, 19290-19300.
21. Stewart, G. R., Robertson, B. D., Young, D. B., Tuberculosis: a problem with persistence. Nat. Rev. Microbiol. 2003, 1, 97-105.
22. Sharpe, M. L., Gao, C., Kendall, S. L., Baker, E. N. et al., The structure and unusual protein chemistry of hypoxic response protein 1, a latency antigen and highly expressed member of the DosR regulon in Mycobacterium tuberculosis. J. Mol. Biol. 2008, 383, 822-836.
23. Bashir, N., Kounsar, F., Mukhopadhyay, S., Hasnain, S. E., Mycobacterium tuberculosis conserved hypothetical protein rRv2626c modulates macrophage effector functions. Immunology 2010, 130, 34-45.
24. Kaldor, S. W., Kalish, V. J., Davies, J. F., 2nd, Shetty, B. V. et al., Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 1997, 40, 3979-3985.
25. Kim, E. E., Baker, C. T., Dwyer, M. D., Murcko, M. A. et al., Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
26. Sham, H. L., Kempf, D. J., Molla, A., Marsh, K. C. et al., ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 1998, 42, 3218-3224.
27. Miller, J. R., Dunham, S., Mochalkin, I., Banotai, C. et al., A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc. Natl. Acad. Sci. USA 2009, 106, 1737-1742.
28. Mochalkin, I., Miller, J. R., Narasimhan, L., Thanabal, V. et al., Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. ACS Chem. Biol. 2009, 4, 473-483.
29. Lin, T.-W., Melgar, M. M., Kurth, D., Swamidass, S.J. et al., Structure-based inhibitor design of AccD5, an essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 2006, 103, 3072-3077.
30. Luckner, S. R., Liu, N., am Ende, C. W., Tonge, P. J., Kisker, C., A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. J. Biol. Chem. 2010, 285, 14330-14337.
31. Gupta, R. K., Thakur, T. S., Desiraju, G. R., Tyagi, J. S., Structure-based design of DevR inhibitor active against nonreplicating Mycobacterium tuberculosis. J. Med. Chem. 2009, 52, 6324-6334.
32. Kinnings, S. L., Xie, L., Fung, K. H., Jackson, R. M. et al., The Mycobacterium tuberculosis drugome and its polypharmacological implications. PloS One 2010, 6, e1000976.
33. Kruh, N. A., Troudt, J., Izzo, A., Prenni, J. et al., Portrait of a pathogen: The Mycobacterium tuberculosis proteome in vivo. PLoS One 2010, 5, e13938.
34. Dessen, A., Quémard, A., Blanchard, J. S., Jacobs, W. R., Jr., Sacchettini, J. C., Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995, 267, 1638-1641.
35. Bertrand, T., Eady, N. A., Jones, J. N., Jesmin et al., Crystal structure of Mycobacterium tuberculosis catalase-peroxidase. J. Biol. Chem. 2004, 279, 38991-38999.